← Back to Search

Device

Wearable Device for Erectile Dysfunction

N/A
Recruiting
Led By Michael Eisenberg, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and up to 1 month post-baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial uses a small device to help men with erectile dysfunction achieve an erection. It targets men who haven't responded to typical treatments or have erectile issues due to surgery or other health problems. The device works by providing mechanical support to keep the penis firm for sex.

Who is the study for?
This trial is for men over 18 with moderate to severe erectile dysfunction from various causes, such as post-prostate surgery or psychological issues. They must have a female partner willing to participate and be open to trying sexual intercourse.
What is being tested?
The study is testing 'Double-S', a wearable device designed as a minimally invasive solution for those experiencing erectile dysfunction, aiming to improve their condition.
What are the potential side effects?
Potential side effects are not explicitly listed but may include discomfort or skin irritation due to the device's wearability and operation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and up to 1 month post-baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and up to 1 month post-baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in modified International Index of Erectile Dysfunction score

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Double-S armExperimental Treatment1 Intervention
Participants will be asked to use the wearable penile device during intercourse.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Erectile Dysfunction (ED) include PDE5 inhibitors, vacuum erection devices, and minimally invasive erectile devices. PDE5 inhibitors, such as sildenafil, work by increasing vascular nitric oxide (NO) production, which enhances blood flow to the penis. Vacuum erection devices create a vacuum around the penis, drawing blood into the corpora cavernosa and using occlusive rings to maintain the erection. Minimally invasive erectile devices, like the one studied in the trial, aim to provide mechanical support or enhance blood flow with minimal intervention. Understanding these mechanisms is crucial for ED patients as it helps them and their doctors choose the most appropriate treatment based on their specific condition and preferences, potentially improving treatment outcomes and quality of life.
The management of stuttering priapism.Ischaemic priapism: A clinical review.Management of erectile dysfunction post-radical prostatectomy.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,469 Previous Clinical Trials
17,501,737 Total Patients Enrolled
2 Trials studying Erectile Dysfunction
24 Patients Enrolled for Erectile Dysfunction
Michael Eisenberg, MDPrincipal InvestigatorStanford University
2 Previous Clinical Trials
25 Total Patients Enrolled
1 Trials studying Erectile Dysfunction
9 Patients Enrolled for Erectile Dysfunction

Media Library

Double-S (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05451563 — N/A
Erectile Dysfunction Research Study Groups: Double-S arm
Erectile Dysfunction Clinical Trial 2023: Double-S Highlights & Side Effects. Trial Name: NCT05451563 — N/A
Double-S (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05451563 — N/A
~4 spots leftby Jun 2025